@BOOK
  {ref1,
   AUTHOR  = "Kernighan, Brian W. and Ritchie, Dennis M.",
   TITLE   = "{The C Programming Language Second Edition}",
   PUBLISHER = "Prentice-Hall, Inc.",
   YEAR = 1988
  }

@ARTICLE{Chen2010-to,
  title    = "{Chem2Bio2RDF}: a semantic framework for linking and data mining
              chemogenomic and systems chemical biology data",
  author   = "Chen, Bin and Dong, Xiao and Jiao, Dazhi and Wang, Huijun and
              Zhu, Qian and Ding, Ying and Wild, David J",
  abstract = "BACKGROUND: Recently there has been an explosion of new data
              sources about genes, proteins, genetic variations, chemical
              compounds, diseases and drugs. Integration of these data sources
              and the identification of patterns that go across them is of
              critical interest. Initiatives such as Bio2RDF and LODD have
              tackled the problem of linking biological data and drug data
              respectively using RDF. Thus far, the inclusion of chemogenomic
              and systems chemical biology information that crosses the domains
              of chemistry and biology has been very limited RESULTS: We have
              created a single repository called Chem2Bio2RDF by aggregating
              data from multiple chemogenomics repositories that is
              cross-linked into Bio2RDF and LODD. We have also created a
              linked-path generation tool to facilitate SPARQL query
              generation, and have created extended SPARQL functions to address
              specific chemical/biological search needs. We demonstrate the
              utility of Chem2Bio2RDF in investigating polypharmacology,
              identification of potential multiple pathway inhibitors, and the
              association of pathways with adverse drug reactions. CONCLUSIONS:
              We have created a new semantic systems chemical biology resource,
              and have demonstrated its potential usefulness in specific
              examples of polypharmacology, multiple pathway inhibition and
              adverse drug reaction--pathway mapping. We have also demonstrated
              the usefulness of extending SPARQL with cheminformatics and
              bioinformatics functionality.",
  journal  = "BMC Bioinformatics",
  volume   =  11,
  pages    = "255",
  month    =  may,
  year     =  2010,
  language = "en"
}

@ARTICLE{Chen2012-iq,
  title    = "Assessing drug target association using semantic linked data",
  author   = "Chen, Bin and Ding, Ying and Wild, David J",
  abstract = "The rapidly increasing amount of public data in chemistry and
              biology provides new opportunities for large-scale data mining
              for drug discovery. Systematic integration of these heterogeneous
              sets and provision of algorithms to data mine the integrated sets
              would permit investigation of complex mechanisms of action of
              drugs. In this work we integrated and annotated data from public
              datasets relating to drugs, chemical compounds, protein targets,
              diseases, side effects and pathways, building a semantic linked
              network consisting of over 290,000 nodes and 720,000 edges. We
              developed a statistical model to assess the association of drug
              target pairs based on their relation with other linked objects.
              Validation experiments demonstrate the model can correctly
              identify known direct drug target pairs with high precision.
              Indirect drug target pairs (for example drugs which change gene
              expression level) are also identified but not as strongly as
              direct pairs. We further calculated the association scores for
              157 drugs from 10 disease areas against 1683 human targets, and
              measured their similarity using a [Formula: see text] score
              matrix. The similarity network indicates that drugs from the same
              disease area tend to cluster together in ways that are not
              captured by structural similarity, with several potential new
              drug pairings being identified. This work thus provides a novel,
              validated alternative to existing drug target prediction
              algorithms. The web service is freely available at:
              http://chem2bio2rdf.org/slap.",
  journal  = "PLoS Comput. Biol.",
  volume   =  8,
  number   =  7,
  pages    = "e1002574",
  month    =  jul,
  year     =  2012,
  language = "en"
}

@ARTICLE{Oprea2018-cp,
  title    = "Unexplored therapeutic opportunities in the human genome",
  author   = "Oprea, Tudor I and Bologa, Cristian G and Brunak, S{\o}ren and
              Campbell, Allen and Gan, Gregory N and Gaulton, Anna and Gomez,
              Shawn M and Guha, Rajarshi and Hersey, Anne and Holmes, Jayme and
              Jadhav, Ajit and Jensen, Lars Juhl and Johnson, Gary L and
              Karlson, Anneli and Leach, Andrew R and Ma'ayan, Avi and
              Malovannaya, Anna and Mani, Subramani and Mathias, Steven L and
              McManus, Michael T and Meehan, Terrence F and von Mering,
              Christian and Muthas, Daniel and Nguyen, Dac-Trung and
              Overington, John P and Papadatos, George and Qin, Jun and Reich,
              Christian and Roth, Bryan L and Sch{\"u}rer, Stephan C and
              Simeonov, Anton and Sklar, Larry A and Southall, Noel and Tomita,
              Susumu and Tudose, Ilinca and Ursu, Oleg and Vidovic, Du{\v s}ica
              and Waller, Anna and Westergaard, David and Yang, Jeremy J and
              Zahor{\'a}nszky-K{\"o}halmi, Gergely",
  abstract = "This corrects the article DOI: 10.1038/nrd.2018.14.",
  journal  = "Nat. Rev. Drug Discov.",
  volume   =  17,
  number   =  5,
  pages    = "377",
  month    =  may,
  year     =  2018,
  language = "en"
}


@MISC{National_Institutes_of_Health_US_Department_of_Health_and_Human_Services_undated-jt,
  title        = "National Institutes of Health Common Fund",
  booktitle    = "{NIH} Office of Strategic Coordination - The Common Fund",
  author       = "{National Institutes of Health, U.S. Department of Health and
                  Human Services}",
  howpublished = "\url{https://commonfund.nih.gov/}",
  note         = "Accessed: 2020-12-21"
}


@ARTICLE{Keenan2018-sf,
  title    = "The Library of Integrated {Network-Based} Cellular Signatures
              {NIH} Program: {System-Level} Cataloging of Human Cells Response
              to Perturbations",
  author   = "Keenan, Alexandra B and Jenkins, Sherry L and Jagodnik, Kathleen
              M and Koplev, Simon and He, Edward and Torre, Denis and Wang,
              Zichen and Dohlman, Anders B and Silverstein, Moshe C and
              Lachmann, Alexander and Kuleshov, Maxim V and Ma'ayan, Avi and
              Stathias, Vasileios and Terryn, Raymond and Cooper, Daniel and
              Forlin, Michele and Koleti, Amar and Vidovic, Dusica and Chung,
              Caty and Sch{\"u}rer, Stephan C and Vasiliauskas, Jouzas and
              Pilarczyk, Marcin and Shamsaei, Behrouz and Fazel, Mehdi and Ren,
              Yan and Niu, Wen and Clark, Nicholas A and White, Shana and Mahi,
              Naim and Zhang, Lixia and Kouril, Michal and Reichard, John F and
              Sivaganesan, Siva and Medvedovic, Mario and Meller, Jaroslaw and
              Koch, Rick J and Birtwistle, Marc R and Iyengar, Ravi and Sobie,
              Eric A and Azeloglu, Evren U and Kaye, Julia and Osterloh,
              Jeannette and Haston, Kelly and Kalra, Jaslin and Finkbiener,
              Steve and Li, Jonathan and Milani, Pamela and Adam, Miriam and
              Escalante-Chong, Renan and Sachs, Karen and Lenail, Alex and
              Ramamoorthy, Divya and Fraenkel, Ernest and Daigle, Gavin and
              Hussain, Uzma and Coye, Alyssa and Rothstein, Jeffrey and Sareen,
              Dhruv and Ornelas, Loren and Banuelos, Maria and Mandefro, Berhan
              and Ho, Ritchie and Svendsen, Clive N and Lim, Ryan G and
              Stocksdale, Jennifer and Casale, Malcolm S and Thompson, Terri G
              and Wu, Jie and Thompson, Leslie M and Dardov, Victoria and
              Venkatraman, Vidya and Matlock, Andrea and Van Eyk, Jennifer E
              and Jaffe, Jacob D and Papanastasiou, Malvina and Subramanian,
              Aravind and Golub, Todd R and Erickson, Sean D and
              Fallahi-Sichani, Mohammad and Hafner, Marc and Gray, Nathanael S
              and Lin, Jia-Ren and Mills, Caitlin E and Muhlich, Jeremy L and
              Niepel, Mario and Shamu, Caroline E and Williams, Elizabeth H and
              Wrobel, David and Sorger, Peter K and Heiser, Laura M and Gray,
              Joe W and Korkola, James E and Mills, Gordon B and LaBarge, Mark
              and Feiler, Heidi S and Dane, Mark A and Bucher, Elmar and
              Nederlof, Michel and Sudar, Damir and Gross, Sean and Kilburn,
              David F and Smith, Rebecca and Devlin, Kaylyn and Margolis, Ron
              and Derr, Leslie and Lee, Albert and Pillai, Ajay",
  abstract = "The Library of Integrated Network-Based Cellular Signatures
              (LINCS) is an NIH Common Fund program that catalogs how human
              cells globally respond to chemical, genetic, and disease
              perturbations. Resources generated by LINCS include experimental
              and computational methods, visualization tools, molecular and
              imaging data, and signatures. By assembling an integrated picture
              of the range of responses of human cells exposed to many
              perturbations, the LINCS program aims to better understand human
              disease and to advance the development of new therapies.
              Perturbations under study include drugs, genetic perturbations,
              tissue micro-environments, antibodies, and disease-causing
              mutations. Responses to perturbations are measured by transcript
              profiling, mass spectrometry, cell imaging, and biochemical
              methods, among other assays. The LINCS program focuses on
              cellular physiology shared among tissues and cell types relevant
              to an array of diseases, including cancer, heart disease, and
              neurodegenerative disorders. This Perspective describes LINCS
              technologies, datasets, tools, and approaches to data
              accessibility and reusability.",
  journal  = "Cell Syst",
  volume   =  6,
  number   =  1,
  pages    = "13--24",
  month    =  jan,
  year     =  2018,
  keywords = "BD2K; L1000; MCF10A; MEMA; P100; data integration; lincsprogram;
              lincsproject; systems biology; systems pharmacology",
  language = "en"
}


@ARTICLE{Nguyen2017-lo,
  title    = "Pharos: Collating protein information to shed light on the
              druggable genome",
  author   = "Nguyen, Dac-Trung and Mathias, Stephen and Bologa, Cristian and
              Brunak, Soren and Fernandez, Nicolas and Gaulton, Anna and
              Hersey, Anne and Holmes, Jayme and Jensen, Lars Juhl and
              Karlsson, Anneli and Liu, Guixia and Ma'ayan, Avi and Mandava,
              Geetha and Mani, Subramani and Mehta, Saurabh and Overington,
              John and Patel, Juhee and Rouillard, Andrew D and Sch{\"u}rer,
              Stephan and Sheils, Timothy and Simeonov, Anton and Sklar, Larry
              A and Southall, Noel and Ursu, Oleg and Vidovic, Dusica and
              Waller, Anna and Yang, Jeremy and Jadhav, Ajit and Oprea, Tudor I
              and Guha, Rajarshi",
  abstract = "The 'druggable genome' encompasses several protein families, but
              only a subset of targets within them have attracted significant
              research attention and thus have information about them publicly
              available. The Illuminating the Druggable Genome (IDG) program
              was initiated in 2014, has the goal of developing experimental
              techniques and a Knowledge Management Center (KMC) that would
              collect and organize information about protein targets from four
              families, representing the most common druggable targets with an
              emphasis on understudied proteins. Here, we describe two
              resources developed by the KMC: the Target Central Resource
              Database (TCRD) which collates many heterogeneous gene/protein
              datasets and Pharos (https://pharos.nih.gov), a multimodal web
              interface that presents the data from TCRD. We briefly describe
              the types and sources of data considered by the KMC and then
              highlight features of the Pharos interface designed to enable
              intuitive access to the IDG knowledgebase. The aim of Pharos is
              to encourage 'serendipitous browsing', whereby related, relevant
              information is made easily discoverable. We conclude by
              describing two use cases that highlight the utility of Pharos and
              TCRD.",
  journal  = "Nucleic Acids Res.",
  volume   =  45,
  number   = "D1",
  pages    = "D995--D1002",
  month    =  jan,
  year     =  2017,
  language = "en"
}


@ARTICLE{Ursu2018-sc,
  title    = "{DrugCentral} 2018: an update",
  author   = "Ursu, Oleg and Holmes, Jayme and Bologa, Cristian G and Yang,
              Jeremy J and Mathias, Stephen L and Stathias, Vasileios and
              Nguyen, Dac-Trung and Sch{\"u}rer, Stephan and Oprea, Tudor",
  abstract = "DrugCentral is a drug information resource
              (http://drugcentral.org) open to the public since 2016 and
              previously described in the 2017 Nucleic Acids Research Database
              issue. Since the 2016 release, 103 new approved drugs were
              updated. The following new data sources have been included: Food
              and Drug Administration (FDA) Adverse Event Reporting System
              (FAERS), FDA Orange Book information, L1000 gene perturbation
              profile distance/similarity matrices and estimated protonation
              constants. New and existing entries have been updated with the
              latest information from scientific literature, drug labels and
              external databases. The web interface has been updated to display
              and query new data. The full database dump and data files are
              available for download from the DrugCentral website.",
  journal  = "Nucleic Acids Res.",
  month    =  oct,
  year     =  2018,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Avram2021-wd,
  title    = "{DrugCentral} 2021 supports drug discovery and repositioning",
  author   = "Avram, Sorin and Bologa, Cristian G and Holmes, Jayme and Bocci,
              Giovanni and Wilson, Thomas B and Nguyen, Dac-Trung and Curpan,
              Ramona and Halip, Liliana and Bora, Alina and Yang, Jeremy J and
              Knockel, Jeffrey and Sirimulla, Suman and Ursu, Oleg and Oprea,
              Tudor I",
  abstract = "DrugCentral is a public resource (http://drugcentral.org) that
              serves the scientific community by providing up-to-date drug
              information, as described in previous papers. The current release
              includes 109 newly approved (October 2018 through March 2020)
              active pharmaceutical ingredients in the US, Europe, Japan and
              other countries; and two molecular entities (e.g. mefuparib) of
              interest for COVID19. New additions include a set of
              pharmacokinetic properties for âˆ¼1000 drugs, and a sex-based
              separation of side effects, processed from FAERS (FDA Adverse
              Event Reporting System); as well as a drug repositioning
              prioritization scheme based on the market availability and
              intellectual property rights forFDA approved drugs. In the
              context of the COVID19 pandemic, we also incorporated
              REDIAL-2020, a machine learning platform that estimates
              anti-SARS-CoV-2 activities, as well as the 'drugs in news'
              feature offers a brief enumeration of the most interesting drugs
              at the present moment. The full database dump and data files are
              available for download from the DrugCentral web portal.",
  journal  = "Nucleic Acids Res.",
  volume   =  49,
  number   = "D1",
  pages    = "D1160--D1169",
  month    =  jan,
  year     =  2021,
  language = "en"
}


@MISC{Chen2017-zj,
  title   = "Reversal of cancer gene expression correlates with drug efficacy
             and reveals therapeutic targets",
  author  = "Chen, Bin and Ma, Li and Paik, Hyojung and Sirota, Marina and Wei,
             Wei and Chua, Mei-Sze and So, Samuel and Butte, Atul J",
  journal = "Nature Communications",
  volume  =  8,
  number  =  1,
  year    =  2017
}


@ARTICLE{Bodenreider2004-gn,
  title    = "The Unified Medical Language System ({UMLS)}: integrating
              biomedical terminology",
  author   = "Bodenreider, Olivier",
  abstract = "The Unified Medical Language System (http://umlsks.nlm.nih.gov)
              is a repository of biomedical vocabularies developed by the US
              National Library of Medicine. The UMLS integrates over 2 million
              names for some 900,000 concepts from more than 60 families of
              biomedical vocabularies, as well as 12 million relations among
              these concepts. Vocabularies integrated in the UMLS Metathesaurus
              include the NCBI taxonomy, Gene Ontology, the Medical Subject
              Headings (MeSH), OMIM and the Digital Anatomist Symbolic
              Knowledge Base. UMLS concepts are not only inter-related, but may
              also be linked to external resources such as GenBank. In addition
              to data, the UMLS includes tools for customizing the
              Metathesaurus (MetamorphoSys), for generating lexical variants of
              concept names (lvg) and for extracting UMLS concepts from text
              (MetaMap). The UMLS knowledge sources are updated quarterly. All
              vocabularies are available at no fee for research purposes within
              an institution, but UMLS users are required to sign a license
              agreement. The UMLS knowledge sources are distributed on CD-ROM
              and by FTP.",
  journal  = "Nucleic Acids Res.",
  volume   =  32,
  number   = "Database issue",
  pages    = "D267--70",
  month    =  jan,
  year     =  2004,
  language = "en"
}


@ARTICLE{Cannon2017-af,
  title    = "{TIN-X}: target importance and novelty explorer",
  author   = "Cannon, Daniel C and Yang, Jeremy J and Mathias, Stephen L and
              Ursu, Oleg and Mani, Subramani and Waller, Anna and Sch{\"u}rer,
              Stephan C and Jensen, Lars Juhl and Sklar, Larry A and Bologa,
              Cristian G and Oprea, Tudor I",
  abstract = "Motivation: The increasing amount of peer-reviewed manuscripts
              requires the development of specific mining tools to facilitate
              the visual exploration of evidence linking diseases and proteins.
              Results: We developed TIN-X, the Target Importance and Novelty
              eXplorer, to visualize the association between proteins and
              diseases, based on text mining data processed from scientific
              literature. In the current implementation, TIN-X supports
              exploration of data for G-protein coupled receptors, kinases, ion
              channels, and nuclear receptors. TIN-X supports browsing and
              navigating across proteins and diseases based on ontology
              classes, and displays a scatter plot with two proposed new
              bibliometric statistics: Importance and Novelty. Availability and
              Implementation: http://www.newdrugtargets.org. Contact:
              cbologa@salud.unm.edu.",
  journal  = "Bioinformatics",
  volume   =  33,
  number   =  16,
  pages    = "2601--2603",
  month    =  aug,
  year     =  2017,
  language = "en"
}


@ARTICLE{Egana2009-xo,
  title    = "Physical and functional interaction between the dopamine
              transporter and the synaptic vesicle protein synaptogyrin-3",
  author   = "Ega{\~n}a, Loreto A and Cuevas, Rolando A and Baust, Tracy B and
              Parra, Leonardo A and Leak, Rehana K and Hochendoner, Sarah and
              Pe{\~n}a, Karina and Quiroz, Marisol and Hong, Weimin C and
              Dorostkar, Mario M and Janz, Roger and Sitte, Harald H and
              Torres, Gonzalo E",
  abstract = "Uptake through the dopamine transporter (DAT) represents the
              primary mechanism used to terminate dopaminergic transmission in
              brain. Although it is well known that dopamine (DA) taken up by
              the transporter is used to replenish synaptic vesicle stores for
              subsequent release, the molecular details of this mechanism are
              not completely understood. Here, we identified the synaptic
              vesicle protein synaptogyrin-3 as a DAT interacting protein using
              the split ubiquitin system. This interaction was confirmed
              through coimmunoprecipitation experiments using heterologous cell
              lines and mouse brain. DAT and synaptogyrin-3 colocalized at
              presynaptic terminals from mouse striatum. Using fluorescence
              resonance energy transfer microscopy, we show that both proteins
              interact in live neurons. Pull-down assays with GST (glutathione
              S-transferase) proteins revealed that the cytoplasmic N termini
              of both DAT and synaptogyrin-3 are sufficient for this
              interaction. Furthermore, the N terminus of DAT is capable of
              binding purified synaptic vesicles from brain tissue. Functional
              assays revealed that synaptogyrin-3 expression correlated with
              DAT activity in PC12 and MN9D cells, but not in the non-neuronal
              HEK-293 cells. These changes were not attributed to changes in
              transporter cell surface levels or to direct effect of the
              protein-protein interaction. Instead, the synaptogyrin-3 effect
              on DAT activity was abolished in the presence of the vesicular
              monoamine transporter-2 (VMAT2) inhibitor reserpine, suggesting a
              dependence on the vesicular DA storage system. Finally, we
              provide evidence for a biochemical complex involving DAT,
              synaptogyrin-3, and VMAT2. Collectively, our data identify a
              novel interaction between DAT and synaptogyrin-3 and suggest a
              physical and functional link between DAT and the vesicular DA
              system.",
  journal  = "J. Neurosci.",
  volume   =  29,
  number   =  14,
  pages    = "4592--4604",
  month    =  apr,
  year     =  2009,
  language = "en"
}

@BOOK{Stoker2018-sf,
  title     = "Parkinson's Disease: Pathogenesis and Clinical Aspects",
  author    = "Stoker, Thomas B and Greenland, Julia C",
  abstract  = "Parkinson's disease is an increasingly common neurodegenerative
               condition, which causes not only dysfunction of movement but
               also a broad range of nonmotor features, including mood
               disturbance, sleep dysfunction, autonomic dysfunction, cognitive
               deficits, dementia, and neuropsychiatric symptoms. A major
               conundrum in this condition is understanding its striking
               clinical variability, which encompasses a spectrum from a benign
               phenotype with levodopa-responsive symptoms and minimal
               progression, to a malignant phenotype with rapid progression to
               severe gait dysfunction, falls and dementia. This book
               integrates the considerable expertise of a range of authors from
               different disciplines, from clinicians through to basic
               scientists, to present a comprehensive and up-to-date overview
               of Parkinson's disease. In recent years, we have made
               significant progress in understanding the pathological and
               genetic basis of Parkinson's disease and its heterogeneous
               forms, and the first section of the book is dedicated to
               reviewing this. The variable clinical features of Parkinson's
               disease and its differential diagnosis are then considered. The
               final section provides a detailed overview of treatment
               approaches, including not only pharmacological therapies but
               also surgical therapies including deep brain stimulation and
               cell transplantation strategies. The combination of basic
               biology, clinical knowledge and therapeutics gives this book a
               very broad appeal. It will be of value to clinicians and health
               professionals caring for patients with Parkinson's disease, as
               well as providing an excellent introduction for junior
               researchers entering the field.",
  publisher = "Codon Publications",
  year      =  2018,
  language  = "en"
}


@ARTICLE{Schmitt2017-du,
  title    = "{U18666A}, an activator of sterol regulatory element binding
              protein pathway, modulates presynaptic dopaminergic phenotype of
              {SH-SY5Y} neuroblastoma cells",
  author   = "Schmitt, Mathieu and Dehay, Benjamin and Bezard, Erwan and
              Garcia-Ladona, F Javier",
  abstract = "The therapeutic use of statins has been associated to a reduced
              risk of Parkinson's disease (PD) and may hold neuroprotective
              potential by counteracting the degeneration of dopaminergic
              neurons. Transcriptional activation of the sterol regulatory
              element-binding protein (SREBP) is one of the major downstream
              signaling pathways triggered by the cholesterol-lowering effect
              of statins. In a previous study in neuroblastoma cells, we have
              shown that statins consistently induce the upregulation of
              presynaptic dopaminergic proteins and changes of their function
              and these effects were accompanied by downstream activation of
              SREBP. In this study, we aimed to determine the direct role of
              SREBP pathway in the modulation of dopaminergic phenotype. We
              demonstrate that treatment of SH-SY5Y cells with U18666A, an
              SREBP activator, increases the translocation of SREBPs into the
              nucleus, increases the expression of SREBP-1, SREBP-2, and of the
              presynaptic dopaminergic markers such as vesicular monoamine
              transporter 2, synaptic vesicle glycoprotein 2 A and 2 C,
              synaptogyrin-3, and tyrosine hydroxylase. The addition of SREBP
              inhibitor, PF-429242, blocks the increase of U18666A-induced
              expression of SREBPs and presynaptic markers. Our results, in
              line with previously reported effects of statins, demonstrate
              that direct stimulation of SREBP translocation is associated to
              differentiation toward a dopaminergic-like phenotype and suggest
              that SREBP-mediated transcriptional activity may lead to the
              restoration of the presynaptic dopamine markers and may
              contribute to neuroprotection of dopaminergic neurons. These
              findings further support the potential protective role of statin
              in PD and shed light upon SREBP as a potential new target for
              developing disease-modifying treatment in PD.",
  journal  = "Synapse",
  volume   =  71,
  number   =  9,
  month    =  sep,
  year     =  2017,
  keywords = "PF-429242; Parkinson's disease; S1P; SREBP; cholesterol;
              dopamine; neurodifferentiation; nuclear translocation; statins",
  language = "en"
}

@MISC{Schmitt2016-bf,
  title   = "Harnessing the trophic and modulatory potential of statins in a
             dopaminergic cell line",
  author  = "Schmitt, Mathieu and Dehay, Benjamin and Bezard, Erwan and Javier
             Garcia-Ladona, F",
  journal = "Synapse",
  volume  =  70,
  number  =  3,
  pages   = "71--86",
  year    =  2016
}

@ARTICLE{Sirota2011-tl,
  title    = "Discovery and preclinical validation of drug indications using
              compendia of public gene expression data",
  author   = "Sirota, Marina and Dudley, Joel T and Kim, Jeewon and Chiang,
              Annie P and Morgan, Alex A and Sweet-Cordero, Alejandro and Sage,
              Julien and Butte, Atul J",
  abstract = "The application of established drug compounds to new therapeutic
              indications, known as drug repositioning, offers several
              advantages over traditional drug development, including reduced
              development costs and shorter paths to approval. Recent
              approaches to drug repositioning use high-throughput experimental
              approaches to assess a compound's potential therapeutic
              qualities. Here, we present a systematic computational approach
              to predict novel therapeutic indications on the basis of
              comprehensive testing of molecular signatures in drug-disease
              pairs. We integrated gene expression measurements from 100
              diseases and gene expression measurements on 164 drug compounds,
              yielding predicted therapeutic potentials for these drugs. We
              recovered many known drug and disease relationships using
              computationally derived therapeutic potentials and also predict
              many new indications for these 164 drugs. We experimentally
              validated a prediction for the antiulcer drug cimetidine as a
              candidate therapeutic in the treatment of lung adenocarcinoma,
              and demonstrate its efficacy both in vitro and in vivo using
              mouse xenograft models. This computational method provides a
              systematic approach for repositioning established drugs to treat
              a wide range of human diseases.",
  journal  = "Sci. Transl. Med.",
  volume   =  3,
  number   =  96,
  pages    = "96ra77",
  month    =  aug,
  year     =  2011,
  language = "en"
}

@MISC{Li2013-th,
  title   = "Pathway-based drug repositioning using causal inference",
  author  = "Li, Jiao and Lu, Zhiyong",
  journal = "BMC Bioinformatics",
  volume  =  14,
  number  = "S16",
  year    =  2013
}

@MISC{Callahan2013-ev,
  title   = "{Bio2RDF} Release 2: Improved Coverage, Interoperability and
             Provenance of Life Science Linked Data",
  author  = "Callahan, Alison and Cruz-Toledo, Jos{\'e} and Ansell, Peter and
             Dumontier, Michel",
  journal = "The Semantic Web: Semantics and Big Data",
  pages   = "200--212",
  year    =  2013
}

@ARTICLE{Himmelstein2015-ie,
  title    = "Heterogeneous Network Edge Prediction: A Data Integration
              Approach to Prioritize {Disease-Associated} Genes",
  author   = "Himmelstein, Daniel S and Baranzini, Sergio E",
  abstract = "The first decade of Genome Wide Association Studies (GWAS) has
              uncovered a wealth of disease-associated variants. Two important
              derivations will be the translation of this information into a
              multiscale understanding of pathogenic variants and leveraging
              existing data to increase the power of existing and future
              studies through prioritization. We explore edge prediction on
              heterogeneous networks--graphs with multiple node and edge
              types--for accomplishing both tasks. First we constructed a
              network with 18 node types--genes, diseases, tissues,
              pathophysiologies, and 14 MSigDB (molecular signatures database)
              collections--and 19 edge types from high-throughput
              publicly-available resources. From this network composed of
              40,343 nodes and 1,608,168 edges, we extracted features that
              describe the topology between specific genes and diseases. Next,
              we trained a model from GWAS associations and predicted the
              probability of association between each protein-coding gene and
              each of 29 well-studied complex diseases. The model, which
              achieved 132-fold enrichment in precision at 10\% recall,
              outperformed any individual domain, highlighting the benefit of
              integrative approaches. We identified pleiotropy, transcriptional
              signatures of perturbations, pathways, and protein interactions
              as influential mechanisms explaining pathogenesis. Our method
              successfully predicted the results (with AUROC = 0.79) from a
              withheld multiple sclerosis (MS) GWAS despite starting with only
              13 previously associated genes. Finally, we combined our network
              predictions with statistical evidence of association to propose
              four novel MS genes, three of which (JAK2, REL, RUNX3) validated
              on the masked GWAS. Furthermore, our predictions provide
              biological support highlighting REL as the causal gene within its
              gene-rich locus. Users can browse all predictions online
              (http://het.io). Heterogeneous network edge prediction
              effectively prioritized genetic associations and provides a
              powerful new approach for data integration across multiple
              domains.",
  journal  = "PLoS Comput. Biol.",
  volume   =  11,
  number   =  7,
  pages    = "e1004259",
  month    =  jul,
  year     =  2015,
  language = "en"
}

@ARTICLE{Himmelstein2017-jy,
  title    = "Systematic integration of biomedical knowledge prioritizes drugs
              for repurposing",
  author   = "Himmelstein, Daniel Scott and Lizee, Antoine and Hessler,
              Christine and Brueggeman, Leo and Chen, Sabrina L and Hadley,
              Dexter and Green, Ari and Khankhanian, Pouya and Baranzini,
              Sergio E",
  abstract = "The ability to computationally predict whether a compound treats
              a disease would improve the economy and success rate of drug
              approval. This study describes Project Rephetio to systematically
              model drug efficacy based on 755 existing treatments. First, we
              constructed Hetionet (neo4j.het.io), an integrative network
              encoding knowledge from millions of biomedical studies. Hetionet
              v1.0 consists of 47,031 nodes of 11 types and 2,250,197
              relationships of 24 types. Data were integrated from 29 public
              resources to connect compounds, diseases, genes, anatomies,
              pathways, biological processes, molecular functions, cellular
              components, pharmacologic classes, side effects, and symptoms.
              Next, we identified network patterns that distinguish treatments
              from non-treatments. Then, we predicted the probability of
              treatment for 209,168 compound-disease pairs (het.io/repurpose).
              Our predictions validated on two external sets of treatment and
              provided pharmacological insights on epilepsy, suggesting they
              will help prioritize drug repurposing candidates. This study was
              entirely open and received realtime feedback from 40 community
              members.",
  journal  = "Elife",
  volume   =  6,
  month    =  sep,
  year     =  2017,
  keywords = "computational biology; drug repurposing; heterogeneous networks;
              human; machine learning; systems biology",
  language = "en"
}

@ARTICLE{Digles2018-qs,
  title    = "Accessing the Open {PHACTS} Discovery Platform with Workflow
              Tools",
  author   = "Digles, Daniela and Caracoti, Andrei and Jacoby, Edgar",
  abstract = "The Open PHACTS Discovery Platform integrates several public
              databases, which can be of interest when annotating the results
              of a phenotypic screening campaign. Workflow tools provide
              easy-to-customize possibilities to access the platform. Here, we
              describe how to create such workflows for two different workflow
              tools (KNIME and Pipeline Pilot), including a protocol to
              annotate compounds (e.g., phenotypic screening hits) with
              compound classification, known protein targets, and
              classifications of the targets.",
  journal  = "Methods Mol. Biol.",
  volume   =  1787,
  pages    = "183--193",
  year     =  2018,
  keywords = "KNIME; Open PHACTS; Phenotypic screening; Pipeline Pilot;
              Workflow tool",
  language = "en"
}

@ARTICLE{Szklarczyk2019-bc,
  title    = "{STRING} v11: protein-protein association networks with increased
              coverage, supporting functional discovery in genome-wide
              experimental datasets",
  author   = "Szklarczyk, Damian and Gable, Annika L and Lyon, David and Junge,
              Alexander and Wyder, Stefan and Huerta-Cepas, Jaime and
              Simonovic, Milan and Doncheva, Nadezhda T and Morris, John H and
              Bork, Peer and Jensen, Lars J and Mering, Christian von",
  abstract = "Proteins and their functional interactions form the backbone of
              the cellular machinery. Their connectivity network needs to be
              considered for the full understanding of biological phenomena,
              but the available information on protein-protein associations is
              incomplete and exhibits varying levels of annotation granularity
              and reliability. The STRING database aims to collect, score and
              integrate all publicly available sources of protein-protein
              interaction information, and to complement these with
              computational predictions. Its goal is to achieve a comprehensive
              and objective global network, including direct (physical) as well
              as indirect (functional) interactions. The latest version of
              STRING (11.0) more than doubles the number of organisms it
              covers, to 5090. The most important new feature is an option to
              upload entire, genome-wide datasets as input, allowing users to
              visualize subsets as interaction networks and to perform gene-set
              enrichment analysis on the entire input. For the enrichment
              analysis, STRING implements well-known classification systems
              such as Gene Ontology and KEGG, but also offers additional, new
              classification systems based on high-throughput text-mining as
              well as on a hierarchical clustering of the association network
              itself. The STRING resource is available online at
              https://string-db.org/.",
  journal  = "Nucleic Acids Res.",
  volume   =  47,
  number   = "D1",
  pages    = "D607--D613",
  month    =  jan,
  year     =  2019,
  language = "en"
}

@ARTICLE{Morton2019-le,
  title    = "{ROBOKOP}: an abstraction layer and user interface for knowledge
              graphs to support question answering",
  author   = "Morton, Kenneth and Wang, Patrick and Bizon, Chris and Cox,
              Steven and Balhoff, James and Kebede, Yaphet and Fecho, Karamarie
              and Tropsha, Alexander",
  abstract = "SUMMARY: Knowledge graphs (KGs) are quickly becoming a
              common-place tool for storing relationships between entities from
              which higher-level reasoning can be conducted. KGs are typically
              stored in a graph-database format, and graph-database queries can
              be used to answer questions of interest that have been posed by
              users such as biomedical researchers. For simple queries, the
              inclusion of direct connections in the KG and the storage and
              analysis of query results are straightforward; however, for
              complex queries, these capabilities become exponentially more
              challenging with each increase in complexity of the query. For
              instance, one relatively complex query can yield a KG with
              hundreds of thousands of query results. Thus, the ability to
              efficiently query, store, rank and explore sub-graphs of a
              complex KG represents a major challenge to any effort designed to
              exploit the use of KGs for applications in biomedical research
              and other domains. We present Reasoning Over Biomedical Objects
              linked in Knowledge Oriented Pathways as an abstraction layer and
              user interface to more easily query KGs and store, rank and
              explore query results. AVAILABILITY AND IMPLEMENTATION: An
              instance of the ROBOKOP UI for exploration of the ROBOKOP
              Knowledge Graph can be found at http://robokop.renci.org. The
              ROBOKOP Knowledge Graph can be accessed at
              http://robokopkg.renci.org. Code and instructions for building
              and deploying ROBOKOP are available under the MIT open software
              license from https://github.com/NCATS-Gamma/robokop.
              SUPPLEMENTARY INFORMATION: Supplementary data are available at
              Bioinformatics online.",
  journal  = "Bioinformatics",
  volume   =  35,
  number   =  24,
  pages    = "5382--5384",
  month    =  dec,
  year     =  2019,
  language = "en"
}

@ARTICLE{Greene2015-ix,
  title    = "Understanding multicellular function and disease with human
              tissue-specific networks",
  author   = "Greene, Casey S and Krishnan, Arjun and Wong, Aaron K and
              Ricciotti, Emanuela and Zelaya, Rene A and Himmelstein, Daniel S
              and Zhang, Ran and Hartmann, Boris M and Zaslavsky, Elena and
              Sealfon, Stuart C and Chasman, Daniel I and FitzGerald, Garret A
              and Dolinski, Kara and Grosser, Tilo and Troyanskaya, Olga G",
  abstract = "Tissue and cell-type identity lie at the core of human physiology
              and disease. Understanding the genetic underpinnings of complex
              tissues and individual cell lineages is crucial for developing
              improved diagnostics and therapeutics. We present genome-wide
              functional interaction networks for 144 human tissues and cell
              types developed using a data-driven Bayesian methodology that
              integrates thousands of diverse experiments spanning tissue and
              disease states. Tissue-specific networks predict lineage-specific
              responses to perturbation, identify the changing functional roles
              of genes across tissues and illuminate relationships among
              diseases. We introduce NetWAS, which combines genes with
              nominally significant genome-wide association study (GWAS) P
              values and tissue-specific networks to identify disease-gene
              associations more accurately than GWAS alone. Our webserver,
              GIANT, provides an interface to human tissue networks through
              multi-gene queries, network visualization, analysis tools
              including NetWAS and downloadable networks. GIANT enables
              systematic exploration of the landscape of interacting genes that
              shape specialized cellular functions across more than a hundred
              human tissues and cell types.",
  journal  = "Nat. Genet.",
  volume   =  47,
  number   =  6,
  pages    = "569--576",
  month    =  jun,
  year     =  2015,
  language = "en"
}

@ARTICLE{Ochoa2020-ew,
  title     = "Open Targets Platform: supporting systematic drug--target
               identification and prioritisation",
  author    = "Ochoa, David and Hercules, Andrew and Carmona, Miguel and
               Suveges, Daniel and Gonzalez-Uriarte, Asier and Malangone,
               Cinzia and Miranda, Alfredo and Fumis, Luca and Carvalho-Silva,
               Denise and Spitzer, Michaela and Baker, Jarrod and Ferrer,
               Javier and Raies, Arwa and Razuvayevskaya, Olesya and
               Faulconbridge, Adam and Petsalaki, Eirini and Mutowo, Prudence
               and Machlitt-Northen, Sandra and Peat, Gareth and McAuley,
               Elaine and Ong, Chuang Kee and Mountjoy, Edward and Ghoussaini,
               Maya and Pierleoni, Andrea and Papa, Eliseo and Pignatelli,
               Miguel and Koscielny, Gautier and Karim, Mohd and
               Schwartzentruber, Jeremy and Hulcoop, David G and Dunham, Ian
               and McDonagh, Ellen M",
  abstract  = "Abstract. The Open Targets Platform
               (https://www.targetvalidation.org/) provides users with a
               queryable knowledgebase and user interface to aid systematic
               targe",
  journal   = "Nucleic Acids Res.",
  publisher = "Oxford Academic",
  volume    =  49,
  number    = "D1",
  pages     = "D1302--D1310",
  month     =  nov,
  year      =  2020,
  keywords  = "cancer; drug delivery systems; genome; safety; technology;
               user-computer interface; genetics; genetic analysis; adverse
               effects of medication; drug discovery; genome-wide association
               study; marketing; crispr; biobanks; knowledge bases; datasets",
  language  = "en"
}

@ARTICLE{Lysenko2016-ba,
  title    = "Representing and querying disease networks using graph databases",
  author   = "Lysenko, Artem and Roznov{\u a}{\c t}, Irina A and Saqi, Mansoor
              and Mazein, Alexander and Rawlings, Christopher J and Auffray,
              Charles",
  abstract = "BACKGROUND: Systems biology experiments generate large volumes of
              data of multiple modalities and this information presents a
              challenge for integration due to a mix of complexity together
              with rich semantics. Here, we describe how graph databases
              provide a powerful framework for storage, querying and
              envisioning of biological data. RESULTS: We show how graph
              databases are well suited for the representation of biological
              information, which is typically highly connected, semi-structured
              and unpredictable. We outline an application case that uses the
              Neo4j graph database for building and querying a prototype
              network to provide biological context to asthma related genes.
              CONCLUSIONS: Our study suggests that graph databases provide a
              flexible solution for the integration of multiple types of
              biological data and facilitate exploratory data mining to support
              hypothesis generation.",
  journal  = "BioData Min.",
  volume   =  9,
  pages    = "23",
  month    =  jul,
  year     =  2016,
  keywords = "Computational approach; Disease management platform; Graph
              database; Neo4j graph; Protein-centric framework; Systems
              medicine",
  language = "en"
}

@ARTICLE{Mathias2013-hj,
  title    = "The {CARLSBAD} database: a confederated database of chemical
              bioactivities",
  author   = "Mathias, Stephen L and Hines-Kay, Jarrett and Yang, Jeremy J and
              Zahoransky-Kohalmi, Gergely and Bologa, Cristian G and Ursu, Oleg
              and Oprea, Tudor I",
  abstract = "Many bioactivity databases offer information regarding the
              biological activity of small molecules on protein targets.
              Information in these databases is often hard to resolve with
              certainty because of subsetting different data in a variety of
              formats; use of different bioactivity metrics; use of different
              identifiers for chemicals and proteins; and having to access
              different query interfaces, respectively. Given the multitude of
              data sources, interfaces and standards, it is challenging to
              gather relevant facts and make appropriate connections and
              decisions regarding chemical-protein associations. The CARLSBAD
              database has been developed as an integrated resource, focused on
              high-quality subsets from several bioactivity databases, which
              are aggregated and presented in a uniform manner, suitable for
              the study of the relationships between small molecules and
              targets. In contrast to data collection resources, CARLSBAD
              provides a single normalized activity value of a given type for
              each unique chemical-protein target pair. Two types of scaffold
              perception methods have been implemented and are available for
              datamining: HierS (hierarchical scaffolds) and MCES (maximum
              common edge subgraph). The 2012 release of CARLSBAD contains 439
              985 unique chemical structures, mapped onto 1,420 889 unique
              bioactivities, and annotated with 277 140 HierS scaffolds and 54
              135 MCES chemical patterns, respectively. Of the 890 323 unique
              structure-target pairs curated in CARLSBAD, 13.95\% are
              aggregated from multiple structure-target values: 94 975 are
              aggregated from two bioactivities, 14 544 from three, 7 930 from
              four and 2214 have five bioactivities, respectively. CARLSBAD
              captures bioactivities and tags for 1435 unique chemical
              structures of active pharmaceutical ingredients (i.e. 'drugs').
              CARLSBAD processing resulted in a net 17.3\% data reduction for
              chemicals, 34.3\% reduction for bioactivities, 23\% reduction for
              HierS and 25\% reduction for MCES, respectively. The CARLSBAD
              database supports a knowledge mining system that provides
              non-specialists with novel integrative ways of exploring chemical
              biology space to facilitate knowledge mining in drug discovery
              and repurposing. Database URL:
              http://carlsbad.health.unm.edu/carlsbad/.",
  journal  = "Database",
  volume   =  2013,
  pages    = "bat044",
  month    =  jun,
  year     =  2013,
  language = "en"
}

@ARTICLE{Yoon2017-jv,
  title    = "Use of Graph Database for the Integration of Heterogeneous
              Biological Data",
  author   = "Yoon, Byoung-Ha and Kim, Seon-Kyu and Kim, Seon-Young",
  abstract = "Understanding complex relationships among heterogeneous
              biological data is one of the fundamental goals in biology. In
              most cases, diverse biological data are stored in relational
              databases, such as MySQL and Oracle, which store data in multiple
              tables and then infer relationships by multiple-join statements.
              Recently, a new type of database, called the graph-based
              database, was developed to natively represent various kinds of
              complex relationships, and it is widely used among computer
              science communities and IT industries. Here, we demonstrate the
              feasibility of using a graph-based database for complex
              biological relationships by comparing the performance between
              MySQL and Neo4j, one of the most widely used graph databases. We
              collected various biological data (protein-protein interaction,
              drug-target, gene-disease, etc.) from several existing sources,
              removed duplicate and redundant data, and finally constructed a
              graph database containing 114,550 nodes and 82,674,321
              relationships. When we tested the query execution performance of
              MySQL versus Neo4j, we found that Neo4j outperformed MySQL in all
              cases. While Neo4j exhibited a very fast response for various
              queries, MySQL exhibited latent or unfinished responses for
              complex queries with multiple-join statements. These results show
              that using graph-based databases, such as Neo4j, is an efficient
              way to store complex biological relationships. Moreover, querying
              a graph database in diverse ways has the potential to reveal
              novel relationships among heterogeneous biological data.",
  journal  = "Genomics Inform.",
  volume   =  15,
  number   =  1,
  pages    = "19--27",
  month    =  mar,
  year     =  2017,
  keywords = "Neo4j; biological network; data mining; graph database;
              heterogeneous biological data; query performance",
  language = "en"
}

@ARTICLE{Have2013-hx,
  title    = "Are graph databases ready for bioinformatics?",
  author   = "Have, Christian Theil and Jensen, Lars Juhl",
  journal  = "Bioinformatics",
  volume   =  29,
  number   =  24,
  pages    = "3107--3108",
  month    =  dec,
  year     =  2013,
  language = "en"
}

@MISC{JCC_Consulting_Inc_acting_on_behalf_of_an_unincorporated_association_of_ISO_Graph_Query_Language_Proponents_and_licensed_under_the_Apache_License_Version_2_undated-lm,
  title        = "{GQL} Standard",
  booktitle    = "Graph Query Language {GQL}",
  author       = "{JCC Consulting, Inc. , acting on behalf of an unincorporated
                  association of ISO Graph Query Language Proponents, and
                  licensed under the Apache License, Version 2.}",
  howpublished = "\url{https://www.gqlstandards.org/}",
  note         = "Accessed: 2020-12-21"
}

@MISC{Neo4j_Inc_undated-hy,
  title        = "Neo4j Licensing Overview",
  booktitle    = "Neo4j",
  author       = "{Neo4j, Inc.}",
  howpublished = "\url{https://neo4j.com/licensing/}",
  note         = "Accessed: 2020-12-21"
}
@MISC{Neo4j_Inc_undated-ly,
  title        = "Neo4j Python Driver",
  booktitle    = "Neo4j",
  author       = "{Neo4j, Inc.}",
  howpublished = "\url{https://neo4j.com/docs/api/python-driver/current/}",
  note         = "Accessed: 2020-12-21"
}

@MISC{Dgraph_Labs_Inc_undated-ko,
  title        = "Dgraph",
  booktitle    = "Dgraph",
  author       = "{Dgraph Labs, Inc.}",
  howpublished = "\url{https://dgraph.io/}",
  note         = "Accessed: 2020-12-21"
}

@MISC{Amazon_Web_Services_Inc_undated-lu,
  title        = "Amazon Neptune",
  booktitle    = "Amazon Neptune",
  author       = "{Amazon Web Services, Inc.}",
  howpublished = "\url{https://aws.amazon.com/neptune/}",
  note         = "Accessed: 2020-12-21"
}

@ARTICLE{Subramanian2017-sx,
  title    = "A Next Generation Connectivity Map: {L1000} Platform and the
              First 1,000,000 Profiles",
  author   = "Subramanian, Aravind and Narayan, Rajiv and Corsello, Steven M
              and Peck, David D and Natoli, Ted E and Lu, Xiaodong and Gould,
              Joshua and Davis, John F and Tubelli, Andrew A and Asiedu, Jacob
              K and Lahr, David L and Hirschman, Jodi E and Liu, Zihan and
              Donahue, Melanie and Julian, Bina and Khan, Mariya and Wadden,
              David and Smith, Ian C and Lam, Daniel and Liberzon, Arthur and
              Toder, Courtney and Bagul, Mukta and Orzechowski, Marek and
              Enache, Oana M and Piccioni, Federica and Johnson, Sarah A and
              Lyons, Nicholas J and Berger, Alice H and Shamji, Alykhan F and
              Brooks, Angela N and Vrcic, Anita and Flynn, Corey and Rosains,
              Jacqueline and Takeda, David Y and Hu, Roger and Davison, Desiree
              and Lamb, Justin and Ardlie, Kristin and Hogstrom, Larson and
              Greenside, Peyton and Gray, Nathanael S and Clemons, Paul A and
              Silver, Serena and Wu, Xiaoyun and Zhao, Wen-Ning and
              Read-Button, Willis and Wu, Xiaohua and Haggarty, Stephen J and
              Ronco, Lucienne V and Boehm, Jesse S and Schreiber, Stuart L and
              Doench, John G and Bittker, Joshua A and Root, David E and Wong,
              Bang and Golub, Todd R",
  abstract = "We previously piloted the concept of a Connectivity Map (CMap),
              whereby genes, drugs, and disease states are connected by virtue
              of common gene-expression signatures. Here, we report more than a
              1,000-fold scale-up of the CMap as part of the NIH LINCS
              Consortium, made possible by a new, low-cost, high-throughput
              reduced representation expression profiling method that we term
              L1000. We show that L1000 is highly reproducible, comparable to
              RNA sequencing, and suitable for computational inference of the
              expression levels of 81\% of non-measured transcripts. We further
              show that the expanded CMap can be used to discover mechanism of
              action of small molecules, functionally annotate genetic variants
              of disease genes, and inform clinical trials. The 1.3 million
              L1000 profiles described here, as well as tools for their
              analysis, are available at https://clue.io.",
  journal  = "Cell",
  volume   =  171,
  number   =  6,
  pages    = "1437--1452.e17",
  month    =  nov,
  year     =  2017,
  keywords = "Functional genomics; chemical biology; gene expression profiling",
  language = "en"
}

@MISC{IDG-KMC_Illuminating_the_Druggable_Genome_Knowledge_Management_Center_undated-pn,
  title        = "{IDG-KMC} Target Central Resource Database",
  booktitle    = "Target Central Resource Database",
  author       = "{IDG-KMC (Illuminating the Druggable Genome Knowledge
                  Management Center)}",
  howpublished = "\url{http://juniper.health.unm.edu/tcrd/}",
  note         = "Accessed: 2020-11-30"
}

@ARTICLE{Hripcsak2015-xo,
  title    = "Observational Health Data Sciences and Informatics ({OHDSI)}:
              Opportunities for Observational Researchers",
  author   = "Hripcsak, George and Duke, Jon D and Shah, Nigam H and Reich,
              Christian G and Huser, Vojtech and Schuemie, Martijn J and
              Suchard, Marc A and Park, Rae Woong and Wong, Ian Chi Kei and
              Rijnbeek, Peter R and van der Lei, Johan and Pratt, Nicole and
              Nor{\'e}n, G Niklas and Li, Yu-Chuan and Stang, Paul E and
              Madigan, David and Ryan, Patrick B",
  abstract = "The vision of creating accessible, reliable clinical evidence by
              accessing the clincial experience of hundreds of millions of
              patients across the globe is a reality. Observational Health Data
              Sciences and Informatics (OHDSI) has built on learnings from the
              Observational Medical Outcomes Partnership to turn methods
              research and insights into a suite of applications and
              exploration tools that move the field closer to the ultimate goal
              of generating evidence about all aspects of healthcare to serve
              the needs of patients, clinicians and all other decision-makers
              around the world.",
  journal  = "Stud. Health Technol. Inform.",
  volume   =  216,
  pages    = "574--578",
  year     =  2015,
  language = "en"
}

@ARTICLE{Hripcsak2019-ho,
  title    = "Facilitating phenotype transfer using a common data model",
  author   = "Hripcsak, George and Shang, Ning and Peissig, Peggy L and
              Rasmussen, Luke V and Liu, Cong and Benoit, Barbara and Carroll,
              Robert J and Carrell, David S and Denny, Joshua C and Dikilitas,
              Ozan and Gainer, Vivian S and Howell, Kayla Marie and Klann,
              Jeffrey G and Kullo, Iftikhar J and Lingren, Todd and Mentch,
              Frank D and Murphy, Shawn N and Natarajan, Karthik and Pacheco,
              Jennifer A and Wei, Wei-Qi and Wiley, Ken and Weng, Chunhua",
  abstract = "BACKGROUND: Implementing clinical phenotypes across a network is
              labor intensive and potentially error prone. Use of a common data
              model may facilitate the process. METHODS: Electronic Medical
              Records and Genomics (eMERGE) sites implemented the Observational
              Health Data Sciences and Informatics (OHDSI) Observational
              Medical Outcomes Partnership (OMOP) Common Data Model across
              their electronic health record (EHR)-linked DNA biobanks. Two
              previously implemented eMERGE phenotypes were converted to OMOP
              and implemented across the network. RESULTS: It was feasible to
              implement the common data model across sites, with laboratory
              data producing the greatest challenge due to local encoding.
              Sites were then able to execute the OMOP phenotype in less than
              one day, as opposed to weeks of effort to manually implement an
              eMERGE phenotype in their bespoke research EHR databases. Of the
              sites that could compare the current OMOP phenotype
              implementation with the original eMERGE phenotype implementation,
              specific agreement ranged from 100\% to 43\%, with disagreements
              due to the original phenotype, the OMOP phenotype, changes in
              data, and issues in the databases. Using the OMOP query as a
              standard comparison revealed differences in the original
              implementations despite starting from the same definitions, code
              lists, flowcharts, and pseudocode. CONCLUSION: Using a common
              data model can dramatically speed phenotype implementation at the
              cost of having to populate that data model, though this will
              produce a net benefit as the number of phenotype implementations
              increases. Inconsistencies among the implementations of the
              original queries point to a potential benefit of using a common
              data model so that actual phenotype code and logic can be shared,
              mitigating human error in reinterpretation of a narrative
              phenotype definition.",
  journal  = "J. Biomed. Inform.",
  volume   =  96,
  pages    = "103253",
  month    =  aug,
  year     =  2019,
  keywords = "Common data model; Electronic health records; Phenotyping",
  language = "en"
}

@ARTICLE{Napolitano2016-ya,
  title    = "Drug-set enrichment analysis: a novel tool to investigate drug
              mode of action",
  author   = "Napolitano, Francesco and Sirci, Francesco and Carrella, Diego
              and di Bernardo, Diego",
  abstract = "MOTIVATION: Automated screening approaches are able to rapidly
              identify a set of small molecules inducing a desired phenotype
              from large small-molecule libraries. However, the resulting set
              of candidate molecules is usually very diverse pharmacologically,
              thus little insight on the shared mechanism of action (MoA)
              underlying their efficacy can be gained. RESULTS: We introduce a
              computational method (Drug-Set Enrichment Analysis-DSEA) based on
              drug-induced gene expression profiles, which is able to identify
              the molecular pathways that are targeted by most of the drugs in
              the set. By diluting drug-specific effects unrelated to the
              phenotype of interest, DSEA is able to highlight
              phenotype-specific pathways, thus helping to formulate hypotheses
              on the MoA shared by the drugs in the set. We validated the
              method by analysing five different drug-sets related to
              well-known pharmacological classes. We then applied DSEA to
              identify the MoA shared by drugs known to be partially effective
              in rescuing mutant cystic fibrosis transmembrane conductance
              regulator (CFTR) gene function in Cystic Fibrosis. AVAILABILITY
              AND IMPLEMENTATION: The method is implemented as an online web
              tool publicly available at http://dsea.tigem.it. CONTACT:
              dibernardo@tigem.it SUPPLEMENTARY INFORMATION: Supplementary data
              are available at Bioinformatics online.",
  journal  = "Bioinformatics",
  volume   =  32,
  number   =  2,
  pages    = "235--241",
  month    =  jan,
  year     =  2016,
  language = "en"
}


@MISC{Rosenthal1978-in,
  title   = "Combining results of independent studies",
  author  = "Rosenthal, Robert",
  journal = "Psychological Bulletin",
  volume  =  85,
  number  =  1,
  pages   = "185--193",
  year    =  1978
}
